Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer

This publication has 18 references indexed in Scilit:

• Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients
  The Journal of Steroid Biochemistry and Molecular Biology, 1996
• Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients
  The Journal of Steroid Biochemistry and Molecular Biology, 1995
• Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer
  Journal of Endocrinology, 1995
• Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients
  The Journal of Steroid Biochemistry and Molecular Biology, 1995
• Preclinical data for Droloxifene
  Cancer Letters, 1994
• Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
  Breast Cancer Research and Treatment, 1994
• Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: Preliminary results of a double-blind dose-finding phase II trial
  European Journal Of Cancer, 1992
• Japanese Early Phase II Study of Droloxifene in the Treatment of Advanced Breast Cancer Preliminary Dose-Finding Study
  American Journal of Clinical Oncology, 1991
• European Early Phase II Dose-Finding Study of Droloxifene in Advanced Breast Cancer
  American Journal of Clinical Oncology, 1991
• Assessment of response to therapy in advanced breast cancer
  Published by Elsevier ,1977